MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- ALEMBIC PHARMACEUTICALS LTD. (pharmaceuticals)
- Latest 8 Quarter Result
ALEMBIC PHARMA Quarterly Results (APLL)
Here are the latest quarterly results of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA financial fact sheet and ALEMBIC PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
ALEMBIC PHARMA Quarterly Results
| No. of Mths Qtr. Ending |
3
Dec-17* |
3
Mar-18* |
3
Jun-18* |
3
Sep-18* |
3
Dec-18* |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 8,400 | 8,533 | 8,625 | 11,271 | 10,182 | 9,270 | 9,489 | 12,409 | |
| Other income | Rs m | 3 | 6 | 1 | 24 | 35 | 34 | 33 | 4 | |
| Turnover | Rs m | 8,404 | 8,540 | 8,626 | 11,294 | 10,217 | 9,303 | 9,522 | 12,412 | |
| Expenses | Rs m | 6,525 | 6,801 | 7,115 | 8,247 | 7,759 | 7,489 | 7,240 | 8,954 | |
| Gross profit | Rs m | 1,875 | 1,730 | 1,510 | 3,023 | 2,422 | 1,783 | 1,964 | 3,455 | |
| Depreciation | Rs m | 264 | 316 | 276 | 286 | 291 | 300 | 354 | 360 | |
| Interest | Rs m | 8 | 13 | 16 | 58 | 60 | 51 | 50 | 71 | |
| Profit before tax | Rs m | 1,606 | 1,408 | 1,220 | 2,703 | 2,108 | 1,467 | 1,593 | 3,029 | |
| Tax | Rs m | 298 | 385 | 315 | 703 | 400 | 149 | 360 | 525 | |
| Profit after tax | Rs m | 1,309 | 1,022 | 904 | 2,000 | 1,708 | 1,318 | 1,233 | 2,504 | |
| Gross profit margin | % | 22.3 | 20.3 | 17.5 | 26.8 | 23.8 | 19.2 | 20.7 | 27.8 | |
| Effective tax rate | % | 18.5 | 27.4 | 25.9 | 26.0 | 19.0 | 10.2 | 22.6 | 17.3 | |
| Net profit margin | % | 15.6 | 12.0 | 10.5 | 17.7 | 16.8 | 14.2 | 13.0 | 20.2 | |
| Diluted EPS | Rs | 6.9 | 5.4 | 4.8 | 10.6 | 9.1 | 7.0 | 6.5 | 13.3 | |
| Diluted EPS (TTM) | Rs | 22.0 | 22.3 | 23.8 | 27.8 | 29.9 | 31.4 | 33.2 | 35.9 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: ALEMBIC PHARMA 2QFY20 Result Performance Review
More Pharmaceuticals Company Quarterly Results: PANACEA BIOTECH LUPIN FDC LTD. SANOFI INDIA J.B.CHEMICALS
Compare ALEMBIC PHARMA With: PANACEA BIOTECH LUPIN FDC LTD. SANOFI INDIA J.B.CHEMICALS
Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)
In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.
Views on news
ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)
Nov 1, 2019 | Updated on Nov 1, 2019For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)
Aug 21, 2019 | Updated on Aug 21, 2019For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 13, 2019 | Updated on Jun 13, 2019Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.
ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 21, 2018 | Updated on Dec 21, 2018Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
Could this Smallcap Be the Next Page Industries? (Profit Hunter)
Nov 27, 2019A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.
How We Made 12.68% in One Overnight Trade (The 5 Minute Wrapup)
Nov 25, 2019This one trade had my subscribers laughing all the way to the bank.
A Simple, 7-Step Checklist for Your Trading Success
Dec 4, 2019What we can learn from one of the greatest traders to have ever lived.
Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market? (Profit Hunter)
Nov 28, 2019Should you invest in growth stocks or value stocks to make strong returns in this market?
Two Trends to Look at as Sensex Crosses 41,000 Levels 
(Views On News)
Nov 26, 2019
The two trends that are playing out as Sensex touches new record high.
More|
| |
ALEMBIC PHARMA SHARE PRICE
Dec 6, 2019 (Close)
TRACK ALEMBIC PHARMA
- Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ALEMBIC PHARMA
ALEMBIC PHARMA 5-YR ANALYSIS
COMPARE ALEMBIC PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.